Advances in the Treatment of Hodkin's Disease: ASH 2001

The results of several key clinical trials on the management of Hodgkin’s disease were presented at ASH. Notably, investigators from Germany presented data on a dose-intensive BEACOPP supported with Neupogen®, producing a two-year freedom from progression of 91% in newly diagnosed patients with stage II-IV Hodgkin’s disease. Investigators from Memorial Sloan-Kettering Cancer Center (MSKCC) and the EORTC both reported, more ...............